Solos Endoscopy secures U.S. Trademark for MammoView name

NewsGuard 100/100 Score

Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce the Company has secured the U.S. Trademark for the MammoView® name. The MamoView® Breast Endoscopy System offers a state-of-the-art endoscopic technology for detecting early stage breast cancer. The Company's Breast Endoscopy System employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of breast cancers arise.  This equipment will distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods. It performs related intraductal procedures with direct visualization of tissues. In addition, it complements existing diagnosis and treatment with direct endoscopic observation.

Solos Endoscopy, Inc was granted the U.S. trademark registration # 3637510 for the protection of the MammoView® name. A registered trademark on the USPTO's principal register grants a bundle of exclusive rights upon the registered owner, including the right to exclusive use of the mark in relation to the products or services for which it is registered. The law in most jurisdictions also allows the owner of a registered trademark to prevent unauthorized use of the mark in relation to products or services that are identical or "colorfully" similar to the "registered" products or services, and in certain cases, prevent use in relation to entirely dissimilar products or services.

"Securing the trademark for the MammoView brand is a significant asset to the company," stated Bob Segersten CEO of Solos Endoscopy, Inc. " This is not only important to our business domestically, but as we continue or work in achieving the CE Mark, this registration can be used as a basis for obtaining registration in other countries."

SOURCE Solos Endoscopy, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis